Investor Relations

Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings more »

OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources more »

OPKO Lab Receives Accreditation From College of American Pathologists more »

Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference more »

Investor Relations

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put OPKO Health, Inc.'s financial performance into perspective.

  • Events


  • Stock Information


Ticker OPK Exchange NYSE
Last Price 14.49 Change 0.22 up
Open 14.37 Previous Close 14.27
Day High 14.70 Day Low 14.28
52-Week High 15.23 52-Week Low 7.82
Quotes delayed at least 20 minutes. Information provided by eSignal.